Skip to content
Screener

Talphera, Inc. TLPH Q3 2026 earnings

Reported November 12, 2026 · After market close

Revenue-
EPS-$0.05In line
EPS estimate-$0.05
“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”
Vince Angotti

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue--100%
Operating income-$4.1M-20.9%
Net income-$4.0M+9.4%

Balance sheet

See full
Cash & equivalents$10.7M+208%
Total equity$10.7M-44.1%
Total assets$23.6M-23.3%

Cash flow

See full
Operating cash flow-$3.0M-20.9%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$56.58M-4.4%

Returns & leverage

See full
Return on equity-98.1%+16.1pp
Current ratio3.2×-3.6×

Segments

By segment

See full
Single Reportable Segments-—

FAQ

When did Talphera, Inc. report Q3 2026 earnings?
Talphera, Inc. (TLPH) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Talphera, Inc.'s Q3 2026 revenue and EPS?
Talphera, Inc. reported revenue of - and eps of $-0.05 for Q3 2026.
Did Talphera, Inc. beat estimates in Q3 2026?
EPS beat the consensus estimate of $-0.05 by $0.00.
How did Talphera, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $1.0K a year earlier and eps grew 54.5% from $-0.11.
Where can I find Talphera, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-036555) and the 10-Q periodic report (0001437749-26-036598) directly on SEC EDGAR. The filing index links above go to sec.gov.